当前位置 >> 基金会介绍 >> 其他理事
其他理事


陈凯先:

陈凯先,中国科学院院士,中国科学院上海药物研究所研究员、博士生导师;上海中医药大学教授、学术委员会主任。现任《重大新药创制》国家重大科技专项技术副总师,中国药典委员会副主任委员,中国药学会监事长,中华中医药学会副会长。曾任上海巿科协主席(2011-2018)、中科院上海药物所所长(1996-2004)、上海中医药大学校长(2005-2014)、中国中西医结合学会会长(2008-2015)、中国药学会副理事长(2007-2016)。

多年来致力于药物构效关系和新药发现研究,是我国该领域的学术带头人之一。两次担任973计划项目首席科学家,先后承担多项国家、中科院和地方重大科研项目。积极参与国家、中科院和上海市生物医药科技发展战略研究、规划制定和重大项目实施,推动了我国创新药物研发和药物创新技术体系建设。

Member of Chinese academy of sciences, Professor and doctoral supervisor of Shanghai Institute of Materia Medica, Chinese Academy of Sciences; Professor and Director of academic committee of Shanghai University of Traditional Chinese Medicine.

Currently, he is Deputy Chief Specialist of the National Science and Technology Major Project- “Innovative Drug Research & Development”,Deputy Chairman of China Pharmacopoeia Committee, Chief Supervisor of China Pharmaceutical Association and Vice President of China Society of Traditional Chinese Medicine.

He was President of Shanghai Association for Science and Technology(2011-2018), Director of Shanghai Institute of Materia Medica, Chinese Academy of Sciences(1996-2004), President of Shanghai University of Traditional Chinese Medicine(2005-2014), President of Chinese Society of Integrative Medicine(2008-2015),and Vice President of Chinese Pharmaceutical Association (2007-2016).

Over the years, he has devoted himself to the study of structure-activity relationship and new drug discovery,and is one of the leading scientists in this field in China. He has been the chief scientist of “project 973” for two times, and has undertaken a number of National, Chinese Academy of Sciences and local major scientific research projects. He has also actively participated in the National, Chinese Academy of Sciences and Shanghai municipal biomedical science and technology development strategy research, and implementation of major projects. All these have promoted China's innovative drug research and development and construction of technology system for drug innovation, and made contributions to the modernization and internationalization of Traditional Chinese Medicine.



范先群:

范先群,医学博士,教授,主任医师,现任上海交通大学党委副书记、上海交通大学医学院党委书记。

先后入选教育部“长江学者”特聘教授、国家百千万人才工程、国家卫计委有突出贡献中青年专家、上海市领军人才等,当选英国皇家眼科学院Fellow和英国爱丁堡皇家外科医学院Fellowship Ad Hominem。

长期致力于眼眶病和眼肿瘤的临床治疗与基础研究,主持国家863计划、科技部国家重点研发计划等国家级项目13项,发表SCI论文150余篇,获国家科技进步二等奖等13项。获亚太眼科学会杰出贡献奖、中华眼科杰出成就奖、全国优秀科技工作者、全国卫生系统先进工作者、上海市科技精英称号和吴阶平-保罗·杨森医学药学奖等。

Prof. Fan Xianqun is currently Deputy Secretary of the CPC of Shanghai Jiao Tong University, Secretary of the CPC of Shanghai Jiao Tong University School of Medicine.

Prof. Fan was awarded as Chang Jiang Scholarship by Ministry of Education of China, Expert with Outstanding Contributions by the Ministry of Human Resources and Social Security of China. He also was awarded the Fellowship of Royal College of Ophthalmologists (UK) and Fellowship Ad Hominem of Royal College of Surgeons of Edinburgh (UK).

Prof. Fan has been devoting his efforts to investigate orbital diseases and ocular tumors. Prof. Fan was in charge of 13 national research grants, which includes National 863 program, project of National Natural Science Foundation and the Ministry of Science and Technology of China. He has published 150 peer-reviewed SCI papers as the first author or corresponding author.He has received successively 13 awards, such as Second Prize of National Science and Technology Progress Awards.

Prof. Fan was named the Excellent Talent by the Ministry of Health of China, National Excellent Scientific and Technical Talent by the Ministry of Science and Technology of China, the Shanghai Leading Talent by Shanghai Municipal Governmen, the Wu Jieping-Paul Janssen Medical & Pharmaceutical Award.


宁光:

中国工程院院士,上海交通大学医学院附属瑞金医院终身教授。现任上海交通大学医学院附属瑞金医院副院长,国家代谢性疾病临床医学研究中心主任。

同时任中国医师协会内分泌代谢科医师分会会长,中华医学会内分泌学分会前任主任委员,《中华内分泌代谢杂志》总编辑,Journal of Diabetes主编,是教育部长江学者特聘教授、973项目首席科学家。

宁光教授长期从事内分泌代谢病临床与科研工作,尤其在内分泌肿瘤与糖尿病诊治及研究领域成果丰硕。在Science、JAMA、Nat Cell Biol、JACC、Nat Med等SCI杂志发表论文500余篇,获国家科技进步二等奖4项及上海市科技进步一等奖3项。宁光教授获评2017年度树兰医学奖,2014年度中国医师奖、吴阶平医药创新奖、第二届“白求恩式好医生”奖。同时获得“以色列糖尿病联盟终身成就奖”及“美国内分泌医师协会国际内分泌医师奖”。



饶子和

饶子和,清华大学教授,曾任南开大学校长、中国科学院生物物理研究所所长。 

饶子和院士主要从事新发、再发传染病病原体的结构与功能研究,以及创新药物的研发。他在SARS冠状病毒、禽流感病毒、甲肝病毒颗粒结构、疱疹病毒等病毒感染、复制和组装,以及结核分枝杆菌能量和代谢物运输、耐药性和细胞壁合成的结构功能研究中做出了突出贡献。近期,饶子和及其团队在小核糖核酸病毒、疱疹病毒和结核分枝杆菌方面的工作为新型抗病毒和抗结核药物的设计和开发提供了重要的研究基础。迄今为止,已在国际科学期刊上发表同行评审论文360篇,其中包括在Cell, Nature, Science 三大科学杂志的主刊上发表研究论文12篇,被引用逾15,000次。



Zihe Rao, Professor of Tsinghua University, Former President of Nankai University and Former Director-General of the Institute of Biophysics, CAS.

Prof Rao is a structural biologist whose research focus is on the study of pathogenic infectious agents. His work has provided insights into viral infection, replication and assembly, and into energy and metabolite transport, drug resistance and cell wall synthesis in Mycobacteria tuberculosis. His most recent work on picornaviruses, herpesvirus, Mycobacteria tuberculosis provided much-needed structural data for the design and development of new anti-viral and anti-TB drugs. To date, Prof Rao has published 360 peer-reviewed papers in international scientific journals with over 15,000 citations. 


王晓东:

王晓东,博士。1984年毕业于北京师范大学,1991年获美国得克萨斯州西南医学中心生物化学博士。现为北京生命科学研究所资深研究员,所长。

王晓东博士主要致力于人体细胞凋亡的研究,凋亡是细胞的一种特殊生理功能,对人体正常发育和清除损伤细胞起着至关重要的作用。凋亡的缺陷是肿瘤发生的关键步骤。在过去的十几年中,王晓东博士领导的实验室发现了细胞凋亡的生化通路与其作用机理。根据这些研究成果,王晓东博士还研发出针对肿瘤细胞凋亡的新型实验性肿瘤治疗药物。2004年被评为美国科学院院士,2013年入选中国科学院外籍院士,2014年入选欧洲分子生物学组织(EMBO)外籍会员,并获得多项国际生物研究奖,其中包括2006年的“邵逸夫生命科学与医学奖”。

Dr. Xiaodong Wang is currently the Director and Investigator of National Institute of Biological Sciences, Beijing. He received his B.S. degree from Beijing Normal University and his Ph.D. degree of Biochemistry from University of Texas Southwestern Medical Center at Dallas. After his postdoctoral training at the Department of Molecular Genetics at the same school, he started his independent research career at Emory University in Atlanta. He returned to UT-Southwestern in 1996 as a faculty member at the Department of Biochemistry and held the position of George MacGregor Distinguished Professor until he returned to Beijing to take his current position in 2010. He was also an Investigator of Howard Hughes Medical Institute from 1997 to 2010. Dr. Xiaodong Wang’s research centers on the biochemical understanding of programmed cell death in mammalian cells.  Their laboratory is responsible for the discovery of the role of cytochrome c in apoptosis that established the signaling function of mitochondria. Their more recent work identified RIP3 kinase and its substrate MLKL as the core components of a pathway controlling and executing programmed necrosis. For his research achievements, Dr. Xiaodong Wang was elected to be a member of National Academy of Sciences, USA; Foreign-associate member of Chinese Academy of Sciences and European Molecular Biology Organization.

 


王明伟:

王明伟 国家特聘专家、复旦大学药学院院长、国家新药筛选中心主任、国家化合物样品库主任

1982年毕业于上海第一医学院医学系,1989年获得剑桥大学博士学位,2001年起出任中国科学院上海药物研究所研究员,先后出任过973计划、中国科学院知识创新工程重大项目、“国家科技重大专项”和863项目有关新药筛选或药物发现资源平台建设的课题负责人,迄今为止发表英文学术论文207篇,包括5篇《自然》主刊、1篇《科学》主刊和3篇《自然》子刊刊载的创新成果,获得国内外发明专利授权63项,2002年获得上海市“白玉兰纪念奖”,2005年荣获国务院特殊津贴,2011年入选中央“千人计划”(创新人才),2012年获得上海市“白玉兰荣誉奖”,被推选为“全国优秀科技工作者。现为浦东新区人民政府生物医药产业发展资深顾问、上海市浦东新区工程师协会理事长、香港大学荣誉教授、澳门大学兼任教授、中国科学院大学教授、复旦大学双聘教授和上海科技大学特聘教授等。其主要研究成果包括发现首个具有体内实验疗效的小分子B类G蛋白偶联受体激动剂、解析三个B类G蛋白偶联受体的三维分子结构(胰高血糖素受体、胰高血糖素样肽-1受体和1型甲状旁腺素受体)、阐明类胰岛素肽5及其受体(A类G蛋白偶联受体)的糖代谢调节功能以及揭示孤儿型G蛋白偶联受体GPR160与前列腺癌发生发展的相关性。

Following medical practices in Shanghai, Dr. Ming-Wei Wang obtained his Ph.D. from University of Cambridge in 1989. He worked for a couple of US-based biotech companies a year later and served as a consultant to Merck and UNDP on China-related projects in the mid-1990’s. Thereafter, he was engaged in various entrepreneur activities. Dr. Wang joined the faculty of Shanghai Institute of Materia Medica, Chinese Academy of Sciences in 2001 and became Director of the National Center for Drug Screening in 2003. In 2004, he was named by Shanghai Pudong New District Government as a Senior Business Advisor. He founded the Chinese National Compound Library and has been its first director since 2012. Dr. Wang was appointed as Dean, School of Pharmacy, Fudan University in 2015. He is also an editorial board member of Trends in Pharmacological Sciences (TiPS), The Biochemical Journal, Acta Pharmacologica Sinica and ACS Pharmacology and Translational Science. His research achievements include the discovery of a non-peptidic glucagon-like peptide-1 receptor agonist Boc5, determination of the 3-D structures of human glucagon receptor, glucagon-like peptide-1 receptor and parathyroid hormone receptor-1, elucidation of the insulinotrophic effect of insulin-like peptide 5 and identification of the link of GPR160 (an orphan GPCR) and prostate cancer.


吴以芳:

吴以芳,于1996年6月1日从南京理工大学取得国际贸易专业学士学位,并于2005年9月1日从美国圣约瑟夫大学取得高级工商管理(医药营销)硕士学位。

2004 年 4 月加入复星医药集团,现任公司执行董事、总裁及首席执行官。于 2007 年 3 月至 2011 年 4 月期间任江苏万邦总裁,2011 年 4 月至今任江苏万邦董事长兼首席执行官。

现为江苏省第十三届人民代表大会代表:担任的社会职务包括中国药品监督管理研究会常务理事;中国医药新闻信息协会副会长;中国医药企业管理协会副会长以及中国非处方药物协会副会长。



Mr. William Wu, joined Shanghai Fosun Pharmaceutical (Group) Co., Ltd. in April 2004 and is currently the Company’s president and Chief Executive Officer. Mr. Wu has over 30 years of experience in the pharmaceutical industry. He started from Xuzhou Biochemical Pharmaceutical Factory (now known as Wanbang Pharma) and has been the chairman and CEO of Wanbang Pharma since April 2011.

Mr. Wu is currently the Representative of the 13th National People’s Congress of Jiangsu Province, as well as executive member of China Society for Drug Regulation, Vice Chairman of China News of Drug Information Association; Vice Chairman of Chinese Pharmaceutical Enterprises Association; and Vice Chairman of China Nonprescription Medicines Association.  

Mr. Wu graduated from Nanjing University of Science and Technology majoring in international commerce in 1996 and obtained a master degree in business administration from Saint Joseph’s University in 2005.


赵维莅

赵维莅,博士,主任医师,教授,博士生导师,教育部长江学者特聘教授,国家杰出青年科学基金获得者,科技部领军人才,百千万人才国家级人选。上海血液学研究所常务副所长,上海交通大学医学院附属瑞金医院血液内科常务副主任。

致力于淋巴细胞恶性疾病的临床和基础研究,以通讯/第一作者在《NATURE GENETICS》、《BLOOD》、《LANCET HAEMATOLOGY》、《LEUKEMIA》、《AUTOPHAGY》等国际血液学权威杂志发表论著60余篇,总影响因子超过360分,近5 年引证超过1000 次。相关成果获国家科技进步二等奖,教育部自然科学一等奖、科技进步一等奖、华夏医学科技奖一等奖和上海市自然科学牡丹奖(第一完成人)。获得国家发明专利6项。

Zhao Wei-Li, M.D., PhD, Professor of Hematology, Associate Director of Shanghai Institute of Hematology and Associate Chief Physician of Department of Hematology, Shanghai Ruijin Hospital. She is the doctoral supervisor of both Shanghai Jiao Tong University and University Paris VII, foreign member of American Society of Hematology, Vice Secretary General of Chinese Society of Experimental Hematology, Member of Chinese Association of Hematology, and member of the editorial committee of Pathobiology, Biomarker Research, Chinese Journal of Hematology, Chinese Journal of Leukemia & Lymphoma, and Clinical Hematology Journal. She mainly focuses on the clinical and basic research of hematological malignancies, especially the molecular markers and targeted therapy of leukemia and lymphoma. She innovatively proposed the molecular pathways of apoptosis, angiogenesis and cell differentiation involved in lymphoma progression and the availability of targeted therapy for its treatment. She has been awarded Outstanding Achievement Award of Scientific Research from National Ministry of Education and HUA XIA Award of Medicine and Technology from National Ministry of Science and Technology for her research progress and is now leading projects granted by National High Technology Research and Development Program of China, by National Natural Science Foundation of China and several other events on provincial level. She has been honored New Century Excellent Talents in University by State Ministry of Education, Rising-Star by Shanghai Committee of Science and Technology, Shu Guang Scholar by Shanghai Municipal Educational Committee. She has published over 60 articles including those on leading hematology journals like Blood and Leukemia with total impact factors over 200.


郑仲征:

郑仲征,男,出生于1973年,民主建国会委员,上海荻硕贝肯生物科技有限公司创始人、董事长。1993-1998年,就读于福建医科大学临床医学专业,获医学学士学位;2010-2012年,就读于云南大学软件工程专业,获工程硕士学位;2015.9-至今,就读于厦门大学生物化学与分子生物学专业,博士研究生在读。

1998年开始先后在三九医药、罗氏快速诊断、扬子江药业集团、北海国发等从事十余年医药销售与市场管理工作;2007年-2011年就职于华大基因研究院,担任健康事业部COO,为华大基因临床与健康营销队伍创始人;2011年创立上海荻硕贝肯生物科技有限公司。主要社会任职有中国医药卫生文化协会常务理事,中国医药生物技术协会骨组织分会常务委员,深圳市龙岗区政协委员等。

Mr. Zheng Zhongzheng, the president and founder of Shanghai Tissuebank Biotechnology Co., Ltd, born in 1973, member of China Democratic National Construction Association. He has got his bachelor’s degree of medicine in 1998 in Fujian Medical University and got his master’s degree pof software engineering in 2012 in Yunnan University. He is now studying for his doctor's degree in biochemistry and molecular biology in Xiamen university since 2015. He has worked in San-Jiu Medicine, Roche rapid diagnosis, Yangtze River pharmaceutical groups since 1998 and has been engaged in pharmaceutical sales and marketing management for more than ten years. He worked in BGI from 2007 to 2011 to be as the COO in the health department COO clinical and health genomics, who is also the founder of the marketing team of the health department. He started the Tissuebank Company in 2011 with founding team. His main social titles are the executive member of the council in Chinese Medicine Health Culture Association, the standing committee member of the China Association for Pharmaceutical Biotechnology branch of Bone tissue of standing committee, CPPCC member of Shenzhen Longgang District, etc.


版权所有:2014年 上海广慈转化医学发展研究基金会 技术支持:上海屹超
地址:上海广慈转化医学发展研究基金会 电话:021-181818 邮箱:161818616@163.com